Published in Int J Pharm on February 02, 2006
Gd-DTPA Adsorption on Chitosan/Magnetite Nanocomposites. Nanoscale Res Lett (2016) 0.92
Control of solid tumor growth in mice using EGF receptor-targeted RNA replicase-based plasmid DNA. Nanomedicine (Lond) (2012) 0.80
The extent of the uptake of plasmid into the skin determines the immune responses induced by a DNA vaccine applied topically onto the skin. J Pharm Pharmacol (2011) 0.79
Replicase-based plasmid DNA shows anti-tumor activity. BMC Cancer (2011) 0.78
Effect of PEG surface conformation on anticancer activity and blood circulation of nanoemulsions loaded with tocotrienol-rich fraction of palm oil. AAPS J (2013) 0.77
Antitumor activity of tumor-targeted RNA replicase-based plasmid that expresses interleukin-2 in a murine melanoma model. Mol Pharm (2013) 0.76
Effects of PEGylation on the physicochemical properties and in vivo distribution of organic nanotubes. Int J Nanomedicine (2014) 0.75
Gadolinium(III) Complexes with N-Alkyl-N-methylglucamine Surfactants Incorporated into Liposomes as Potential MRI Contrast Agents. Bioinorg Chem Appl (2015) 0.75
In vivo evaluation of neutron capture therapy effectivity using calcium phosphate-based nanoparticles as Gd-DTPA delivery agent. J Cancer Res Clin Oncol (2015) 0.75
Stearoyl gemcitabine nanoparticles overcome resistance related to the over-expression of ribonucleotide reductase subunit M1. J Control Release (2011) 1.59
Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev Vaccines (2010) 1.57
Just getting into cells is not enough: mechanisms underlying 4-(N)-stearoyl gemcitabine solid lipid nanoparticle's ability to overcome gemcitabine resistance caused by RRM1 overexpression. J Control Release (2013) 1.42
Strong antibody responses induced by protein antigens conjugated onto the surface of lecithin-based nanoparticles. J Control Release (2009) 1.20
In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles. Int J Pharm (2011) 1.20
Nanoparticles engineered from lecithin-in-water emulsions as a potential delivery system for docetaxel. Int J Pharm (2009) 1.06
Lysosomal delivery of a lipophilic gemcitabine prodrug using novel acid-sensitive micelles improved its antitumor activity. Bioconjug Chem (2012) 1.00
Targeting of tumor-associated macrophages made possible by PEG-sheddable, mannose-modified nanoparticles. Mol Pharm (2013) 0.97
Nasal immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic-polyribocytidylic acid induced strong mucosal and systemic immunities. Pharm Res (2006) 0.97
Nasal immunization with a dual antigen anthrax vaccine induced strong mucosal and systemic immune responses against toxins and bacilli. Vaccine (2006) 0.97
Immunostimulation of dendritic cells by cationic liposomes. Mol Membr Biol (2006) 0.96
Permeation of antigen protein-conjugated nanoparticles and live bacteria through microneedle-treated mouse skin. Int J Nanomedicine (2011) 0.96
Preparation and characterization of novel coenzyme Q10 nanoparticles engineered from microemulsion precursors. AAPS PharmSciTech (2003) 0.95
Synthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticles. Int J Pharm (2012) 0.93
Microneedle-mediated transcutaneous immunization with plasmid DNA coated on cationic PLGA nanoparticles. J Control Release (2012) 0.92
EGFR-targeted stearoyl gemcitabine nanoparticles show enhanced anti-tumor activity. J Control Release (2011) 0.90
Tumor chemo-immunotherapy using gemcitabine and a synthetic dsRNA. Cancer Biol Ther (2007) 0.89
Towards preserving the immunogenicity of protein antigens carried by nanoparticles while avoiding the cold chain. Int J Pharm (2010) 0.88
The effect of the acid-sensitivity of 4-(N)-stearoyl gemcitabine-loaded micelles on drug resistance caused by RRM1 overexpression. Biomaterials (2012) 0.88
Relationship between the size of nanoparticles and their adjuvant activity: data from a study with an improved experimental design. Eur J Pharm Biopharm (2010) 0.87
Biodistribution and in vivo activities of tumor-associated macrophage-targeting nanoparticles incorporated with doxorubicin. Mol Pharm (2014) 0.87
Strong mucosal and systemic immunities induced by nasal immunization with anthrax protective antigen protein incorporated in liposome-protamine-DNA particles. Pharm Res (2006) 0.86
Immunization by application of DNA vaccine onto a skin area wherein the hair follicles have been induced into anagen-onset stage. Mol Ther (2007) 0.85
Negatively charged liposomes show potent adjuvant activity when simply admixed with protein antigens. Mol Pharm (2011) 0.84
CD4+ T helper cell response is required for memory in CD8+ T lymphocytes induced by a poly(I:C)-adjuvanted MHC I-restricted peptide epitope. J Immunother (2007) 0.84
Transmucosal delivery of testosterone in rabbits using novel bi-layer mucoadhesive wax-film composite disks. J Pharm Sci (2002) 0.83
Nasal immunization with the mixture of PA63, LF, and a PGA conjugate induced strong antibody responses against all three antigens. FEMS Immunol Med Microbiol (2008) 0.82
Biodistribution and tumor-accumulation of gadolinium (Gd) encapsulated in long-circulating liposomes in tumor-bearing mice for potential neutron capture therapy. Int J Pharm (2006) 0.81
Evaluation of the immune response induced by a nasal anthrax vaccine based on the protective antigen protein in anaesthetized and non-anaesthetized mice. J Pharm Pharmacol (2006) 0.81
Localized irradiation of tumors prior to synthetic dsRNA therapy enhanced the resultant anti-tumor activity. Radiother Oncol (2008) 0.80
Transcutaneous DNA immunization following waxing-based hair depilation. J Control Release (2011) 0.80
Solid lipid nanoparticle formulations of docetaxel prepared with high melting point triglycerides: in vitro and in vivo evaluation. Mol Pharm (2014) 0.80
Genetic immunization by jet injection of targeted pDNA-coated nanoparticles. Methods (2003) 0.80
Control of solid tumor growth in mice using EGF receptor-targeted RNA replicase-based plasmid DNA. Nanomedicine (Lond) (2012) 0.80
Nanomedicine: the promise and challenges in cancer chemotherapy. Adv Exp Med Biol (2014) 0.79
The extent of the uptake of plasmid into the skin determines the immune responses induced by a DNA vaccine applied topically onto the skin. J Pharm Pharmacol (2011) 0.79
Silencing of ribonucleotide reductase subunit M1 potentiates the antitumor activity of gemcitabine in resistant cancer cells. Cancer Biol Ther (2012) 0.79
Replicase-based plasmid DNA shows anti-tumor activity. BMC Cancer (2011) 0.78
Targeting primaquine into liver using chylomicron emulsions for potential vivax malaria therapy. Int J Pharm (2005) 0.78
Stearoyl gemcitabine nanoparticles overcome obesity-induced cancer cell resistance to gemcitabine in a mouse postmenopausal breast cancer model. Cancer Biol Ther (2013) 0.77
Transcutaneous DNA immunization following waxing-based hair depilation elicits both humoral and cellular immune responses. Eur J Pharm Biopharm (2012) 0.76
Antitumor activity of tumor-targeted RNA replicase-based plasmid that expresses interleukin-2 in a murine melanoma model. Mol Pharm (2013) 0.76
Gadolinium incorporated reconstituted chylomicron emulsion for potential application in tumor neutron capture therapy. Eur J Pharm Biopharm (2005) 0.76
Applications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapy. Expert Rev Vaccines (2015) 0.76
Highlights from the latest articles on vaccine development using nanoparticles. Nanomedicine (Lond) (2014) 0.75
A nanoparticle depot formulation of 4-(N)-stearoyl gemcitabine shows a strong anti-tumour activity. J Pharm Pharmacol (2012) 0.75
Skin penetration of topically applied white mustard extract and its effects on epidermal Langerhans cells and cytokines. Int J Pharm (2013) 0.75
A thermo-sensitive polymeric gel containing a gadolinium (Gd) compound encapsulated into liposomes significantly extended the retention of the Gd in tumors. Drug Dev Ind Pharm (2008) 0.75